Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects - PubMed (original) (raw)
Review
Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects
Atsushi Makimoto et al. Cancers (Basel). 2024.
Abstract
Retinoids are vitamin A derivatives and include trans-retinoic acid, isotretinoin, tamibarotene, and bexarotene, all of which are currently available for clinical use. The clinical development of retinoid therapy for neuroblastoma has a history spanning more than four decades. The most promising agent is isotretinoin, which can contribute to improving event-free survival in patients with high-risk neuroblastoma by approximately 10% when administered over six months as maintenance therapy. Although isotretinoin is regarded as an essential component in the standard clinical management of high-risk neuroblastoma, its use for this purpose in the US and EU is off-label. To promote isotretinoin use in Japan as a treatment for neuroblastoma, our clinical research team is planning to launch an investigator-initiated, registration-directed clinical trial. The present review article discusses the basic science behind retinoid therapy, pre-clinical/clinical evidence on neuroblastoma, the concept of the proposed clinical trial, and prospects for this therapy.
Keywords: high-risk; isotretinoin; maintenance therapy; neuroblastoma; off-label issue; retinoic acids; retinoid therapy; retinoids; tumor differentiation therapy.
Conflict of interest statement
All the authors declare no conflicts of interest.
Figures
Figure 1
Chemical structure of retinoids used in clinical practice. A natural retinoid molecule consists of four isoprenoid units containing a hydrophobic part, the central polyene linker, and the polar region. Synthetic retinoids are generated by modifying the hydrophobic part and the central polyene linker to increase molecular stability. This figure was designed by authors using Ketcher 2.4.
Figure 2
Coregulator exchange at RXR/RAR heterodimers. RARs function as modulators of transcription by recruiting coregulator complexes having HDAC activity. Retinoids function as a ligand activating or blocking gene transcription mediated via RXR/RAR heterodimers. This figure was designed by the authors. HDAC, histone deacetylase; NCoR, nuclear receptor corepressor complex; RA, retinoic acid; RARE, retinoic acid-response element; SMRT, silencing mediator of retinoic acid and thyroid hormone receptor.
Figure 3
Promises, challenges, and countermeasures of a new tumor differentiation therapy based on retinoids. This figure was designed by the authors based on an illustration by Takashi Mifune with his permission. CAR-T cell, chimeric antigen receptor (CAR)-expressing T cells; DDS, drug delivery system; Rx, treatment.
Similar articles
- Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.
Masetti R, Biagi C, Zama D, Vendemini F, Martoni A, Morello W, Gasperini P, Pession A. Masetti R, et al. Adv Ther. 2012 Sep;29(9):747-62. doi: 10.1007/s12325-012-0047-3. Epub 2012 Aug 28. Adv Ther. 2012. PMID: 22941525 Review. - Retinoid therapy of childhood cancer.
Reynolds CP, Lemons RS. Reynolds CP, et al. Hematol Oncol Clin North Am. 2001 Oct;15(5):867-910. doi: 10.1016/s0889-8588(05)70256-2. Hematol Oncol Clin North Am. 2001. PMID: 11765378 Review. - Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature.
Duvalyan A, Cha A, Goodarzian F, Arkader A, Villablanca JG, Marachelian A. Duvalyan A, et al. Pediatr Blood Cancer. 2020 Aug;67(8):e28236. doi: 10.1002/pbc.28236. Epub 2020 May 9. Pediatr Blood Cancer. 2020. PMID: 32386124 Review. - Retinoid therapy of high-risk neuroblastoma.
Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Reynolds CP, et al. Cancer Lett. 2003 Jul 18;197(1-2):185-92. doi: 10.1016/s0304-3835(03)00108-3. Cancer Lett. 2003. PMID: 12880980 Review. - Targeting ATP7A to increase the sensitivity of neuroblastoma cells to retinoid therapy.
Cheung BB, Marshall GM. Cheung BB, et al. Curr Cancer Drug Targets. 2011 Sep;11(7):826-36. doi: 10.2174/156800911796798968. Curr Cancer Drug Targets. 2011. PMID: 21762080 Review.
Cited by
- The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes.
Esposito M, Amory JK, Kang Y. Esposito M, et al. J Exp Med. 2024 Sep 2;221(9):e20240519. doi: 10.1084/jem.20240519. Epub 2024 Aug 12. J Exp Med. 2024. PMID: 39133222 Free PMC article. Review. - Effects of Anionic Liposome Delivery of All-_Trans_-Retinoic Acid on Neuroblastoma Cell Differentiation.
Minò A, Lopez F, Barbaro R, Barile M, Ambrosone L, Colella M. Minò A, et al. Biomimetics (Basel). 2024 Apr 24;9(5):257. doi: 10.3390/biomimetics9050257. Biomimetics (Basel). 2024. PMID: 38786467 Free PMC article. - EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness.
Cocchi S, Greco V, Sidarovich V, Vigna J, Broso F, Corallo D, Zasso J, Re A, Rosatti EF, Longhi S, Defant A, Ladu F, Sanna V, Adami V, D'Agostino VG, Sturlese M, Sechi M, Aveic S, Mancini I, Sighel D, Quattrone A. Cocchi S, et al. Int J Mol Sci. 2024 Apr 27;25(9):4795. doi: 10.3390/ijms25094795. Int J Mol Sci. 2024. PMID: 38732012 Free PMC article.
References
- Park J.R., Hogarty M.D., Bagatell R., Schleiermacher G., Mosse Y.P., Maris J.M. Neuroblastoma. In: Blaney S.M., Adamson P.C., Helman L.J., editors. Pizzo and Poplack’s Pediatric Oncology. Wolters Kluwer; Alphen aan den Rijn, The Netherlands: 2021. pp. 647–672.
- Cohn S.L., Pearson A.D.J., London W.B., Monclair T., Ambros P.F., Brodeur G.M., Faldum A., Hero B., Iehara T., Machin D., et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. J. Clin. Oncol. 2009;27:289–297. doi: 10.1200/JCO.2008.16.6785. - DOI - PMC - PubMed
- Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N. Engl. J. Med. 2010;363:1324–1334. doi: 10.1056/NEJMoa0911123. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources